Questions, answered from the record
Thymosin Alpha-1 FAQ
Direct answers, each grounded in the published literature and cited where a number is claimed.
How long should you take thymosin alpha 1?
Trial durations varied by indication, not by recommendation. Sepsis protocols ran five to seven days; chronic hepatitis regimens ran weeks to months at 1.6 mg subcutaneous twice weekly; a lung-cancer adjunct study dosed weekly for up to twelve months [4][9]. These are study-attributed durations in defined populations — not a course anyone should set for themselves.
How long does it take for thymosin alpha 1 to work?
The literature reports immunological endpoints, not a felt onset. Pharmacologically the peptide peaks in blood within 1-2 hours and clears within about a day [8], but the immune effects (T-cell and HLA-DR changes) were measured over days to weeks in trials [2][6]. There is no established timeline for any subjective effect, since the action is biochemical rather than something a person feels.
What is the dosing protocol for thymosin alpha 1?
Studied protocols, reported as research data: 1.6 mg subcutaneous twice weekly for chronic hepatitis [9]; 1.6 mg subcutaneous every 12 hours for five to seven days in sepsis trials [2][3]; single doses across 0.8-6.4 mg and multiple-dose regimens of 1.6-16 mg over five to seven days in the broader review [4]. This site reports protocols; it does not prescribe one.
How much thymosin alpha 1 should I take?
This is a literature digest, so it cannot answer that — there is no "should" here. What the studies used is on the record: a 0.8-6.4 mg single-dose range and a common 1.6 mg subcutaneous twice weekly chronic regimen [4][9], each tied to a specific studied population. Any decision about use belongs with a qualified clinician, not a website.
When is the best time to take thymosin alpha 1?
No trial established an optimal time of day. Studies dosed on fixed schedules — twice weekly, daily, or every 12 hours depending on the indication [2][9] — driven by the indication and the peptide's roughly 2-hour half-life [8], not by a circadian rationale. The published record simply does not contain a best-time finding to report.
What dose of thymosin alpha 1 are people running?
Community reports skew toward the studied chronic regimen — around 1.6 mg subcutaneous twice weekly — but these are unverified self-reports, not data [4][9]. This site reports the trial-studied amounts as research context, not what anyone should run. Self-directed use falls outside every approved indication and outside the evidence.
How long until thymosin alpha 1 results show up?
Trials measured immunological results over days to weeks — restored T-cell counts and reversed exhaustion in COVID-19 cohorts [6], improved HLA-DR in sepsis [2]. There is no reliable timeline for a felt result, and because the peptide is an immune modulator, many people in the research-use community report noticing nothing at all (anecdotal, not data).
Can you stack thymosin alpha 1 with other peptides?
The published research does not characterize peptide "stacks"; the corpus lists no studied combinations with other research peptides. The combinations that are studied are clinical — with antivirals such as lamivudine or entecavir in hepatitis B [12], or alongside chemo- and immunotherapy in oncology [7]. Anything beyond that is community practice, not evidence, and this site does not advise on it.
How is thymosin alpha 1 administered?
By subcutaneous injection in essentially every clinical trial — a shot under the skin from lyophilized peptide reconstituted before use [4]. Mechanistic studies used in-vitro systems and preclinical work used murine routes [5][10], but the human clinical record is a subcutaneous-injection record. There is no established oral or intranasal route.
What is the half-life of thymosin alpha 1?
About 2 hours after subcutaneous injection in humans, with time-to-peak near 1-2 hours, peak concentration of 30-80 mcg/L, and clearance toward baseline within roughly 24 hours [8]. The immunological effect outlasts that short plasma presence, which is why intermittent dosing is workable despite the brief half-life.
What is thymosin alpha 1?
A 28-amino-acid, N-terminally acetylated thymic peptide isolated from calf thymus (thymosin fraction 5), purified and sequenced by Goldstein and colleagues in 1977 [1]. It is an immune modulator cleaved in the body from prothymosin alpha; the synthetic, sequence-identical drug is called thymalfasin [1][4].
What does thymosin alpha 1 do?
It modulates immunity at the innate-adaptive interface — signalling through TLR2 and TLR9 on dendritic cells to drive their maturation and antigen presentation, which matures T-cells and tips them toward a Th1 response, while a parallel IDO arm generates regulatory T-cells [5]. The net effect is dual: lifting suppressed immunity and restraining over-firing.
What is thymosin alpha 1 used for?
Abroad, thymalfasin is approved for chronic hepatitis B and as an immune adjuvant [4]. In trials it has been studied as an immunostimulatory adjuvant in cancer (melanoma, hepatocellular carcinoma, lung cancer) [7], in sepsis [2][3], and in COVID-19 [6]. It is not approved for marketing in the United States [4].
Is thymosin alpha 1 FDA-approved?
No. Thymosin Alpha-1 (thymalfasin) is not FDA-approved for marketing in the United States; US availability is limited to investigational and compounding contexts [4]. It is approved as a drug in roughly 35 other countries. Some historical US orphan-drug designations existed for specific indications, but those are not marketing approvals.
What is TA1 peptide?
TA1 (Tα1) is shorthand for the same 28-amino-acid acetylated thymic immune peptide — Thymosin Alpha-1 — purified and sequenced by Goldstein and colleagues in 1977 [1]. The abbreviation always refers to this immune modulator, never to a different compound.
Who should not take thymosin alpha 1?
The literature flags theoretical caution for people with established autoimmune disease (an immunostimulant could in principle worsen autoimmunity) [16] and for solid-organ transplant recipients on intentional immunosuppression [5]; pregnancy and lactation are unstudied [4]. These are mechanistic cautions, not absolute rules — any such decision belongs with a clinician, and this site gives no medical advice.
Is TB-500 the same as thymosin alpha 1?
No. TB-500 is thymosin beta-4, a different 43-amino-acid actin-binding peptide studied for tissue repair — a different sequence, size, mechanism, and use [1]. Thymosin Alpha-1 is a 28-amino-acid immune modulator. They share only a family name. TB-500 is the one on prohibited-substance lists; this peptide is not it.
How does thymosin alpha 1 make you feel?
The research-use community most often reports feeling nothing in particular — unsurprising for an immune modulator whose action is biochemical rather than felt (anecdotal, not clinical evidence). Some describe a vague sense of resilience or fewer colds over a season; a minority report a transient flu-like day [4]. No trial measured a subjective "feel."
Is thymosin alpha 1 safe to take?
Its documented safety profile is benign: across 600,000-plus post-marketing patients, injection-site reactions were the dominant event, with occasional transient flu-like symptoms and no documented organ toxicity at studied doses [15][4]. The real risk-adders are research-grade quality (unregulated material) and population-specific cautions [4][16] — not the molecule's own pharmacology. This is not safety advice for any individual.
Does thymosin alpha 1 help cancer?
A reappraisal frames it as an immunostimulatory adjuvant used alongside chemo- and immunotherapy in melanoma, hepatocellular carcinoma, and lung cancer — potentially helping "turn a cold tumour hot" and easing checkpoint-inhibitor toxicity [7]. It is an adjuvant in combination protocols, not a standalone cancer treatment, and the evidence is developmental rather than definitive.
Is thymosin alpha 1 worth it?
That depends on the setting, and the honest answer is uneven. The evidence is strongest in chronic viral hepatitis [12] and the tolerability is good [15]. But the largest rigorous sepsis trial was null (hazard ratio 0.99) [3], the COVID-19 evidence is mixed, and it is not US-approved [4]. "Interesting and well tolerated, oversold outside hepatitis" is a fair reading.
Does thymosin affect aging?
Circulating Thymosin Alpha-1 declines with age, and the immune system weakens with age (immunosenescence), which is why vaccine-adjuvant research has explored the peptide in older adults [1]. But "declines with age" is not the same as "reverses aging" — no trial shows it slows aging itself, and the corpus makes no such anti-aging claim.